Recruiting

Anti-GD2 ADC M3554 in Advanced Solid Tumors

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(11 sites)

United States

Dana-Farber Cancer Institute, Boston, Massachusetts

Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc, New York, New York

The University of Texas MD Anderson Cancer Center, Houston, Texas

Belgium

UZ Leuven, Leuven

France

Institut Bergonié - Service d'Oncologie Médicale, Bordeaux

Centre Oscar Lambret - cancerologie generale, Lille

Centre Leon Berard - Service d'Oncologie Medicale, Lyon

Centre Antoine Lacassagne - Service d'Hématologie Oncologie, Nice

Japan

National Cancer Center Hospital, Chūōku

Switzerland

Universitaetsspital Zuerich - Klinik fuer Neurologie, Zurich

United Kingdom

Royal Marsden Hospital-Sutton - Dept of Oncology (Surrey), Sutton, Surrey